<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02358980</url>
  </required_header>
  <id_info>
    <org_study_id>73/2014</org_study_id>
    <nct_id>NCT02358980</nct_id>
  </id_info>
  <brief_title>Kidney Therapy for Free Light Chain Removal in Patients With Multiple Myeloma &amp; Cast Nephropathy</brief_title>
  <acronym>KEEPER</acronym>
  <official_title>KIDNEY THERAPY FOR FREE LIGHT CHAIN REMOVAL IN PATIENTS WITH MULTIPLE MYELOMA &amp; CAST NEPHROPATHY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcispedale Santa Maria Nuova-IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcispedale Santa Maria Nuova-IRCCS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Free light chain (FLC) removal haemodialysis will increase the rate of renal
      recovery in patients with cast nephropathy, severe renal failure and de novo multiple
      myeloma.

      This study will evaluate patients with multiple myeloma and severe renal failure treated with
      KIDNEY Therapy (previously called SUPRA HFR) to remove free light chains.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational study performed to investigate the clinical benefit of FLC removal
      by KIDNEY therapy system in patients with cast nephropathy, dialysis dependent renal failure
      and de novo multiple myeloma. Recruitment commenced in July 2014, in total 20 patients will
      be recruited. Participants will be treated with, KIDNEY therapy system (Bellco Mirandola,
      Modena, Italy) . The KIDNEY system is a kind of haemodiafiltration that utilizes separated
      convection, diffusion and adsorption. The sorbent cartridge has a high affinity for FLC (both
      κ and λ) but is able to re-infuse albumin, avoiding the need for albumin perfusions. The
      KIDNEY therapy will be undertaken over an intensive treatment schedule. The primary outcome
      for the study is independence of dialysis in 3 month. Secondary outcomes are: duration
      dialysis, reduction of serum FLC levels, myeloma response and survival.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Independence of haemodialysis at 3 months from enrollment</measure>
    <time_frame>3 months from enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficency of KIDNEY therapy system with respect to reduced sFLC levels</measure>
    <time_frame>21 days from enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of HD from renal recover</measure>
    <time_frame>3 months from enrollment</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Cast Nephropathy</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>Participants will receive FLC removal HD undertaken using an extended dialysis schedule on KIDNEY therapy system. Treatments (4 hours each) were carried out for 8 consecutive days and then every other day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>KIDNEY therapy</intervention_name>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cast nephropathy, dialysis dependent renal failure and de novo multiple
        myeloma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18 years

          -  Dialysis dependent acute renal failure

          -  Fulfils diagnostic criteria for the diagnosis of symptomatic de novo multiple myeloma

          -  Abnormal serum FLC ratio and a sFLC concentration &gt; 500 mg/L

          -  Myeloma kidney demonstrated on a renal biopsy (cast nephropathy)

          -  Ability to give informed consent to partake in study

          -  Commencement of study within 10 days of presenting to enrolling unit

        Exclusion Criteria:

          -  Known advanced chronic renal failure (CKD stage IV 4-5; eGFR &lt;30mls/min/1.73m2) or
             evidence of significant chronic damage on renal biopsy

          -  Amyloidosis or light chain deposition disease on renal biopsy

          -  Previous treatment of multiple myeloma with chemotherapy

          -  Haemodynamic instability that precludes unsupported dialysis renal replacement therapy

          -  Significant cardiac disease

          -  Active uncontrolled infection

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nephrology and Dialysis Unit ASMN IRCCS</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Pasquali, MD</last_name>
      <phone>+39 0522296492</phone>
      <email>sonia.pasquali@asmn.re.it</email>
    </contact>
    <contact_backup>
      <last_name>Francesco Iannuzzella, MD</last_name>
      <phone>+39 0522296491</phone>
      <email>francesco.iannuzzella@asmn.re.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Winearls CG. Acute myeloma kidney. Kidney Int. 1995 Oct;48(4):1347-61. Review.</citation>
    <PMID>8569099</PMID>
  </results_reference>
  <results_reference>
    <citation>Haubitz M, Peest D. Myeloma--new approaches to combined nephrological-haematological management. Nephrol Dial Transplant. 2006 Mar;21(3):582-90. Epub 2006 Jan 5. Review.</citation>
    <PMID>16396976</PMID>
  </results_reference>
  <results_reference>
    <citation>Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, Hattersley J, Evans ND, Chappell MJ, Cook M, Goehl H, Storr M, Bradwell AR. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007 Mar;18(3):886-95. Epub 2007 Jan 17.</citation>
    <PMID>17229909</PMID>
  </results_reference>
  <results_reference>
    <citation>Hutchison CA, Bladé J, Cockwell P, Cook M, Drayson M, Fermand JP, Kastritis E, Kyle R, Leung N, Pasquali S, Winearls C; International Kidney and Monoclonal Gammopathy Research Group. Novel approaches for reducing free light chains in patients with myeloma kidney. Nat Rev Nephrol. 2012 Feb 21;8(4):234-43. doi: 10.1038/nrneph.2012.14. Review.</citation>
    <PMID>22349488</PMID>
  </results_reference>
  <results_reference>
    <citation>Testa A, Dejoie T, Lecarrer D, Wratten M, Sereni L, Renaux JL. Reduction of free immunoglobulin light chains using adsorption properties of hemodiafiltration with endogenous reinfusion. Blood Purif. 2010;30(1):34-6. doi: 10.1159/000316684. Epub 2010 Jun 24.</citation>
    <PMID>20588010</PMID>
  </results_reference>
  <results_reference>
    <citation>Pasquali S, Iannuzzella F, Corradini M, Mattei S, Bovino A, Stefani A, Palladino G, Caiazzo M. A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR). J Nephrol. 2015 Apr;28(2):251-4. doi: 10.1007/s40620-014-0130-8. Epub 2014 Aug 23.</citation>
    <PMID>25149172</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2015</study_first_submitted>
  <study_first_submitted_qc>February 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2015</study_first_posted>
  <last_update_submitted>February 6, 2015</last_update_submitted>
  <last_update_submitted_qc>February 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Arcispedale Santa Maria Nuova-IRCCS</investigator_affiliation>
    <investigator_full_name>Sonia Pasquali</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Cast Nephropathy</keyword>
  <keyword>Acute kidney injury</keyword>
  <keyword>KIDNEY THERAPY</keyword>
  <keyword>HFR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

